Article

Melanoma and Men: Don't Wait to Get Checked

We see the highest rates of melanoma related mortality in men over the age of 50. Why is this? Often, men are not getting their skin checked on an annual basis, and even when a change occurs it often goes unnoticed. Older males are in a high risk group for melanoma. Hear first-hand experiences and learn why you should schedule a skin exam soon.

https://vimeo.com/126279944

Related Videos
Image of a woman with blond hai
Dr. Manisha Thakuria in an interview with CURE
Dr. Beth Goldstein in an interview with CURE
Treating Skin Cancer Panel
Dr. Anna C. Pavlick
Lorenzo G. Cohen
Dr. Jedd D. Wolchok
Multidisciplinary Approach Panel
Dr. Nicholas Sanfilippo
Related Content
"FDA" text.
December 13th 2024

FDA Approves Unloxcyt for Locally Advanced, Metastatic Skin Cancer Subset

Ashley Chan
Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of COVID-19 cells.
November 18th 2024

COVID-19 RNA May Be Linked to Metastatic Cancer Regression

Ashley Chan
RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
Image of a doctor examining a patient's skin.
November 4th 2024

Early Data Show Benefits With Ameluz-Photodynamic Therapy in Skin Cancer Subset

Darlene Dobkowski, MA
Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in early data from a phase 3 trial.
Image of camera taking picture of skin.
October 31st 2024

Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma

Spencer Feldman
Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.